Gamma-oryzanol alleviates intervertebral disc degeneration development by intercepting the IL-1β/NLRP3 inflammasome positive cycle.
Gamma-oryzanol
Intervertebral disc degeneration
NF-κB
NLRP3 inflammasome
Nucleus pulposus
Journal
Phytomedicine : international journal of phytotherapy and phytopharmacology
ISSN: 1618-095X
Titre abrégé: Phytomedicine
Pays: Germany
ID NLM: 9438794
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
received:
22
02
2022
revised:
04
05
2022
accepted:
14
05
2022
pubmed:
7
6
2022
medline:
15
6
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Intervertebral disc degeneration (IVDD) is a highly prevalent musculoskeletal disorder characterized by a local inflammatory response associated with the IL-1β/NLRP3 inflammasome positive feedback loop. Rice bran-derived gamma-oryzanol (Ory) as a sterol ferulate has attracted much attention due to its powerful anti-inflammatory, hypoglycemic and hypolipidemic health effects. As a clinical pharmaceutical for autonomic disorders, Ory's role in musculoskeletal degenerative disease remains unknown. This study aims to validate the role of Ory in IVDD and explore the potential mechanism. Establishing the in vitro and in vivo IVDD models to detect the protective effect and molecular mechanism of Ory. The anti-ECM degradation, antioxidant and anti-NLRP3 inflammasome activation effects of Ory on IL-1β-stimulated nucleus pulposus (NP) cells were assessed by immunoblotting and immunofluorescence, etc. MRI, S-O staining and immunohistochemistry were performed to estimate the effects of Ory administration on acupuncture-mediated IVDD in rats at imaging and histological levels. Ory treatment inhibited IL-1β-mediated ECM degradation, oxidative stress and NLRP3 inflammasome activation in NP cells. By interfering with NF-κB signaling and ROS overproduction, Ory interrupted IL-1β/NLRP3-inflammasome positive cycle. In vivo experiments showed that Ory delayed acupuncture-mediated IVDD development. Our results support the potential application of Ory as a therapeutic compound for IVDD.
Sections du résumé
BACKGROUND
BACKGROUND
Intervertebral disc degeneration (IVDD) is a highly prevalent musculoskeletal disorder characterized by a local inflammatory response associated with the IL-1β/NLRP3 inflammasome positive feedback loop. Rice bran-derived gamma-oryzanol (Ory) as a sterol ferulate has attracted much attention due to its powerful anti-inflammatory, hypoglycemic and hypolipidemic health effects. As a clinical pharmaceutical for autonomic disorders, Ory's role in musculoskeletal degenerative disease remains unknown.
PURPOSE
OBJECTIVE
This study aims to validate the role of Ory in IVDD and explore the potential mechanism.
STUDY DESIGN
METHODS
Establishing the in vitro and in vivo IVDD models to detect the protective effect and molecular mechanism of Ory.
METHOD
METHODS
The anti-ECM degradation, antioxidant and anti-NLRP3 inflammasome activation effects of Ory on IL-1β-stimulated nucleus pulposus (NP) cells were assessed by immunoblotting and immunofluorescence, etc. MRI, S-O staining and immunohistochemistry were performed to estimate the effects of Ory administration on acupuncture-mediated IVDD in rats at imaging and histological levels.
RESULTS
RESULTS
Ory treatment inhibited IL-1β-mediated ECM degradation, oxidative stress and NLRP3 inflammasome activation in NP cells. By interfering with NF-κB signaling and ROS overproduction, Ory interrupted IL-1β/NLRP3-inflammasome positive cycle. In vivo experiments showed that Ory delayed acupuncture-mediated IVDD development.
CONCLUSION
CONCLUSIONS
Our results support the potential application of Ory as a therapeutic compound for IVDD.
Identifiants
pubmed: 35660354
pii: S0944-7113(22)00254-9
doi: 10.1016/j.phymed.2022.154176
pii:
doi:
Substances chimiques
IL1B protein, rat
0
Inflammasomes
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nlrp3 protein, rat
0
Phenylpropionates
0
gamma-oryzanol
SST9XCL51M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154176Informations de copyright
Copyright © 2022. Published by Elsevier GmbH.